GlassScriptPhysician profile
Matthew M Mcmahon
NPI 1528244845
$6,663.43
in general payments reported to CMS, 2019-2025
33 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $82.23 · 2021: $305 · 2022: $808 · 2023: $1,296 · 2024: $2,115 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,786 · Education: $46.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,786.37 |
| Education | $46.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,228.45 | 2019-2025 | |
| Janssen Biotech, INC. | $1,101.01 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Aimmune Therapeutics, INC. | $822.82 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $628.14 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $435.08 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Gilead Sciences, INC. | $317.92 | 2019-2025 | |
| Madrigal Pharmaceuticals | $285.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $254.41 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $224.03 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $178.14 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $159.31 | 2023-2025 | Omvoh |
| Celgene Corporation | $122.96 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $105.46 | 2019-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $93.73 | 2022-2024 | |
| Qol Medical, LLC | $89.10 | 2019-2024 | Sucraid, Sucraid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $86.04 | 2020-2024 | Ocaliva |
| Ardelyx, INC. | $79.80 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.28 | 2023 | Cyltezo |
| Organon LLC | $57.76 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $35.90 | 2024 | Bylvay, Iqirvo |
| Celltrion USA INC. | $32.08 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $31.43 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $30.20 | 2025 | |
| Ferring Pharmaceuticals INC. | $29.05 | 2021-2023 | Rebyota |
| Linvatec Corporation | $27.82 | 2019 | |
| Ucb, INC. | $25.81 | 2019-2020 | |
| Conmed Corporation | $24.89 | 2019 | |
| Amgen INC. | $23.55 | 2025 | Uplizna |
| Alfasigma USA, INC. | $16.98 | 2020 | |
| Welch Allyn | $16.90 | 2021 | |
| Daiichi Sankyo INC. | $14.99 | 2023 | Injectafer |
| Braintree Laboratories, INC. | $13.70 | 2023 | Sutab |
| Baxter Healthcare | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.